Oncternal Therapeutics (ONCT) Competitors $1.50 +0.04 (+2.74%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ONCT vs. HCWB, NERV, SYBX, TLPH, CMMB, AIM, UNCY, AVTX, TRIB, and CARAShould you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include HCW Biologics (HCWB), Minerva Neurosciences (NERV), Synlogic (SYBX), Talphera (TLPH), Chemomab Therapeutics (CMMB), AIM ImmunoTech (AIM), Unicycive Therapeutics (UNCY), Avalo Therapeutics (AVTX), Trinity Biotech (TRIB), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Oncternal Therapeutics vs. HCW Biologics Minerva Neurosciences Synlogic Talphera Chemomab Therapeutics AIM ImmunoTech Unicycive Therapeutics Avalo Therapeutics Trinity Biotech Cara Therapeutics Oncternal Therapeutics (NASDAQ:ONCT) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings. Is ONCT or HCWB more profitable? HCW Biologics has a net margin of -978.03% compared to Oncternal Therapeutics' net margin of -1,948.70%. Oncternal Therapeutics' return on equity of -136.10% beat HCW Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Oncternal Therapeutics-1,948.70% -136.10% -108.25% HCW Biologics -978.03%-385.90%-126.44% Does the MarketBeat Community favor ONCT or HCWB? Oncternal Therapeutics received 26 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 27.12% of users gave Oncternal Therapeutics an outperform vote. CompanyUnderperformOutperformOncternal TherapeuticsOutperform Votes3227.12% Underperform Votes8672.88% HCW BiologicsOutperform Votes6100.00% Underperform VotesNo Votes Which has more volatility and risk, ONCT or HCWB? Oncternal Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Which has higher earnings and valuation, ONCT or HCWB? HCW Biologics has higher revenue and earnings than Oncternal Therapeutics. HCW Biologics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncternal Therapeutics$790K5.62-$39.48M-$12.23-0.12HCW Biologics$2.84M5.73-$24.99M-$1.04-0.41 Does the media prefer ONCT or HCWB? In the previous week, Oncternal Therapeutics had 1 more articles in the media than HCW Biologics. MarketBeat recorded 1 mentions for Oncternal Therapeutics and 0 mentions for HCW Biologics. Oncternal Therapeutics' average media sentiment score of 0.00 equaled HCW Biologics'average media sentiment score. Company Overall Sentiment Oncternal Therapeutics Neutral HCW Biologics Neutral Do institutionals & insiders have more ownership in ONCT or HCWB? 16.1% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by insiders. Comparatively, 49.9% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend ONCT or HCWB? Oncternal Therapeutics presently has a consensus price target of $20.00, suggesting a potential upside of 1,233.33%. Given Oncternal Therapeutics' higher possible upside, equities analysts plainly believe Oncternal Therapeutics is more favorable than HCW Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryOncternal Therapeutics beats HCW Biologics on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCT vs. The Competition Export to ExcelMetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E Ratio-0.129.53113.7615.14Price / Sales5.62385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book0.155.324.665.01Net Income-$39.48M$153.56M$119.06M$225.46M7 Day Performance0.67%0.12%0.79%0.37%1 Month Performance20.00%15.23%5.65%3.57%1 Year Performance-77.61%41.16%36.80%29.42% Oncternal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCTOncternal Therapeutics2.479 of 5 stars$1.50+2.7%$20.00+1,233.3%-76.2%$4.44M$790,000.00-0.1230High Trading VolumeHCWBHCW Biologics1.1279 of 5 stars$0.46-7.5%N/A-73.0%$17.49M$3.92M-0.4440Short Interest ↓Gap UpNERVMinerva Neurosciences4.0737 of 5 stars$2.44-0.8%$5.00+104.9%-47.6%$17.06MN/A-0.559Upcoming EarningsAnalyst ForecastNews CoverageSYBXSynlogic2.7858 of 5 stars$1.42-0.7%$30.00+2,012.7%-16.6%$16.61M$3.37M-0.2180News CoveragePositive NewsTLPHTalphera2.4262 of 5 stars$0.97+1.5%$4.50+362.3%N/A$16.54M$398,000.00-1.5219Gap DownCMMBChemomab Therapeutics2.5672 of 5 stars$1.44flat$5.67+293.5%+89.0%$15.91MN/A-1.2620Gap DownAIMAIM ImmunoTech1.3085 of 5 stars$0.27+2.5%$3.00+1,023.2%-43.7%$15.67M$200,000.00-0.4720Gap UpUNCYUnicycive Therapeutics2.9993 of 5 stars$0.42-0.6%$5.13+1,134.9%-10.7%$15.61M$680,000.00-0.409Gap UpAVTXAvalo Therapeutics2.0146 of 5 stars$14.44+9.4%N/A-45.0%$14.93M$807,000.000.0040Gap UpTRIBTrinity Biotech0.7 of 5 stars$1.93+5.5%N/A-24.6%$14.71M$58.65M-0.71480Gap UpCARACara Therapeutics4.1333 of 5 stars$0.27+5.4%$2.32+765.7%-75.5%$14.65M$11.00M-0.1355News Coverage Related Companies and Tools Related Companies HCWB Alternatives NERV Alternatives SYBX Alternatives TLPH Alternatives CMMB Alternatives AIM Alternatives UNCY Alternatives AVTX Alternatives TRIB Alternatives CARA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCT) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
